AU2021244846A1 - Composition and method - Google Patents

Composition and method Download PDF

Info

Publication number
AU2021244846A1
AU2021244846A1 AU2021244846A AU2021244846A AU2021244846A1 AU 2021244846 A1 AU2021244846 A1 AU 2021244846A1 AU 2021244846 A AU2021244846 A AU 2021244846A AU 2021244846 A AU2021244846 A AU 2021244846A AU 2021244846 A1 AU2021244846 A1 AU 2021244846A1
Authority
AU
Australia
Prior art keywords
binding protein
light chain
heavy chain
binding
free light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021244846A
Other languages
English (en)
Inventor
Arunakumari ALAHARI
Rosanne Dunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemalogix Ltd
Original Assignee
Haemalogix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900948A external-priority patent/AU2020900948A0/en
Application filed by Haemalogix Ltd filed Critical Haemalogix Ltd
Publication of AU2021244846A1 publication Critical patent/AU2021244846A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AU2021244846A 2020-03-27 2021-03-26 Composition and method Pending AU2021244846A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2020900948 2020-03-27
AU2020900948A AU2020900948A0 (en) 2020-03-27 Composition and method
US202163200752P 2021-03-25 2021-03-25
US63/200,752 2021-03-25
PCT/IB2021/000171 WO2021191684A1 (en) 2020-03-27 2021-03-26 Composition and method

Publications (1)

Publication Number Publication Date
AU2021244846A1 true AU2021244846A1 (en) 2022-11-24

Family

ID=77890984

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021244846A Pending AU2021244846A1 (en) 2020-03-27 2021-03-26 Composition and method

Country Status (9)

Country Link
US (3) US20240262928A1 (https=)
EP (1) EP4126900A4 (https=)
JP (1) JP7817945B2 (https=)
KR (1) KR20230004543A (https=)
CN (1) CN115551877A (https=)
AU (1) AU2021244846A1 (https=)
BR (1) BR112022019076A2 (https=)
CA (1) CA3176109A1 (https=)
WO (1) WO2021191684A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025213238A1 (en) * 2024-04-12 2025-10-16 HaemaLogiX Ltd Anti-kma antibody formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
US20120114555A1 (en) * 2009-04-07 2012-05-10 Immune System Therapeutics Ltd Method for treating immune disorders
ES2982297T3 (es) * 2009-12-18 2024-10-15 Novartis Ag Método de cromatografía de afinidad
WO2016031932A1 (ja) * 2014-08-27 2016-03-03 田辺三菱製薬株式会社 アルカリ洗浄によるＦｃ領域を有するタンパク質の製造方法
WO2016149088A1 (en) * 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
BR112017022838A2 (en) * 2015-04-23 2018-07-17 Haemalogix Pty. Ltd kappa myeloma antigen chimeric antigen receptors and their uses
EP3492493A4 (en) * 2016-07-28 2020-03-18 Kaneka Corporation METHOD FOR PRODUCING AN ANTIBODY FRAGMENT
EP3774882A1 (en) * 2018-03-29 2021-02-17 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies

Also Published As

Publication number Publication date
KR20230004543A (ko) 2023-01-06
EP4126900A4 (en) 2024-05-29
JP2023518905A (ja) 2023-05-08
US20240262928A1 (en) 2024-08-08
CN115551877A (zh) 2022-12-30
BR112022019076A2 (pt) 2023-01-10
CA3176109A1 (en) 2021-09-30
WO2021191684A1 (en) 2021-09-30
US20240262925A1 (en) 2024-08-08
JP7817945B2 (ja) 2026-02-19
US20260035474A1 (en) 2026-02-05
EP4126900A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
JP7744391B2 (ja) 抗ｖｅｇｆタンパク質組成物及びその製造方法
US9631216B2 (en) Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
AU2014247034B2 (en) A method for increasing pyro-glutamic acid formation of a protein
AU2025287335A1 (en) Continuous manufacturing process for bispecific antibody products
HK1246330A1 (zh) 蛋白质纯化
AU2018326458B2 (en) Method for purifying proteins
WO2015061526A1 (en) Antibody purification
US20260035474A1 (en) Composition and method
WO2012144692A1 (en) Humanized anti-emap ii antibody and use thereof
AU2020221649B2 (en) Producing compositions comprising two or more antibodies.
US20250171536A1 (en) Methods of Bone Marrow Conditioning
US11613571B2 (en) Biopharmaceutical compositions comprising antibody variants
CN113912712B (zh) 抗α-突触核蛋白的单克隆抗体的制备及其应用
US20180312802A1 (en) Methods for modulating production profiles of recombinant proteins in perfusion mode
CN117567625B (zh) 一种抗Claudin18.2单克隆抗体及其应用
CN118638235B (zh) 一种靶向TfR1的纳米抗体及其应用
CN114437204A (zh) 一种抗体或Fc融合蛋白的纯化方法
CN114920842B (zh) 特异性结合pv-1蛋白的抗体或其抗原结合片段及其应用
CN111116749B (zh) 重组的人源化gpc3抗体及其制备和应用
US20240092883A1 (en) Methods of purifying ranibizumab or a ranibizumab variant
AU2023291634A1 (en) Follistatin fusion proteins
CN119998329A (zh) 多特异性多肽复合物